Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $12.1100 (4.22%) ($11.6700 - $12.3600) on Tue. May. 5, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.08% (three month average) | RSI | 74 | Latest Price | $12.1100(4.22%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | FOLD advances 2.1% a week on average for past two weeks. | Market Behavior | Normal for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(54%) XBI(51%) IWO(50%) IWM(45%) IWC(44%) | Factors Impacting FOLD price | FOLD will decline at least -3.54% in a week (0% probabilities). VIXM(-29%) VXX(-15%) UUP(-11%) UNG(-4%) TLT(-4%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.54% (StdDev 7.08%) | Hourly BBV | 0 () | Intraday Trend | 2.2% | | | |
|
5 Day Moving Average | $11.82(2.45%) | 10 Day Moving Average | $12.06(0.41%) | 20 Day Moving Average | $11.44(5.86%) | To recent high | -5.5% | To recent low | 82.7% | Market Cap | $3.127b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |